UK scientists excited by surprise £2-billion government windfall

Abstract

Lilly trial tracked more than 2,100 people diagnosed with mild dementia due to Alzheimer's disease for 18 months. Half received monthly infusions of solanezumab, the other half a placebo. Analysis of people with comparable symptoms in earlier studies of solanezumab had seemed encouraging, but the latest trial indicated only a small cognitive benefit, not… (More)
DOI: 10.1038/nature.2016.21038

Topics

  • Blog articles referencing this paper

  • Presentations referencing similar topics